羟钴胺用于心脏手术血管麻痹:回顾性队列分析
单中心回顾性倾向匹配队列研究纳入2018至2024年体外循环后血管麻痹患者,229对匹配分析显示羟钴胺与1、4、24小时去甲肾上腺素当量输注速率显著降低相关,48小时无显著差异,院内并发症复合终点两组相似。
要点
- 羟钴胺与24小时内去甲肾上腺素当量需求降低相关,48小时无显著差异。
- 初始24小时羟钴胺组去甲肾上腺素当量较参照组降低14%。
- 院内并发症复合终点两组风险相似(OR 1.06,95%CI 0.74-1.54)。
核心结论
- 羟钴胺给药与24小时内血管升压药需求降低相关,但之后无此关联。
- 需要稳健的试验来确定该关系是否因果,以及减少血管升压药使用是否改善实质性临床结局。
研究设计与样本
- 单中心回顾性倾向匹配队列研究,纳入体外循环后发生血管麻痹的患者。
- 2018至2024年共识别2727例(11%)血管麻痹患者,最终分析队列包括229对匹配。
主要发现
- 羟钴胺与1小时去甲肾上腺素当量输注速率中位数降低-0.04(95%CI:-0.07至-0.02;P=0.008)μg kg-1 min-1相关。
- 羟钴胺与4小时去甲肾上腺素当量输注速率中位数降低-0.05(95%CI:-0.07至-0.02;P<0.001)μg kg-1 min-1相关。
- 羟钴胺与24小时去甲肾上腺素当量输注速率中位数降低-0.04(95%CI:-0.06至-0.02;P=0.004)μg kg-1 min-1相关,但48小时无显著差异(-0.02,95%CI:-0.05至0.0;P=0.220)μg kg-1 min-1。
- 初始24小时内,羟钴胺较参照组去甲肾上腺素当量降低14%。
- 院内并发症复合终点(卒中、胸骨伤口感染、肠系膜缺血、肾衰竭和死亡)两组风险相似(OR:1.06;95%CI:0.74-1.54;P=0.745)。
临床怎么用
- 对于体外循环后血管麻痹患者,可考虑羟钴胺作为减少血管升压药需求的辅助策略,但需注意证据来自回顾性研究。
局限性
- 单中心回顾性设计,可能存在残余混杂。
- 需要稳健的试验来确定因果关系及对实质性临床结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vasoplegia during cardiac surgery is common and associated with perioperative mortality. Hydroxocobalamin is a catecholamine-sparing approach for treating vasoplegia. However, there is currently limited evidence to inform its use. METHODS: We conducted a single-centre retrospective propensity-matched cohort study of patients who developed vasoplegia after cardiopulmonary bypass. Our primary outcome was vasopressor requirement, expressed as norepinephrine equivalents (NEE), at 1, 4, 24, and 48 h after treatment. Our secondary outcome was a collapsed composite of in-hospital complications comprising stroke, sternal wound infection, mesenteric ischaemia, renal failure, and death. RESULTS: We identified 2727 (11%) patients with vasoplegia from 2018 to 2024. The final analysis cohort included 229 matched pairs. Hydroxocobalamin administration was associated with a significant reduction in median NEE infusion rates of -0.04 (95% confidence interval [CI]: -0.07 to -0.02; P=0.008) μg kg-1 min-1 at 1 h, -0.05 (95% CI: -0.07 to -0.02; P<0.001) μg kg-1 min-1 at 4 h, and -0.04 (95% CI: -0.06 to -0.02; P=0.004) μg kg-1 min-1 at 24 h, but not at 48 h, -0.02 (95% CI: -0.05 to 0.0; P=0.220) μg kg-1 min-1. Over the initial 24 h, hydroxocobalamin reduced NEE by 14% compared with the reference group. The risk of in-hospital complications was similar in each group (odds ratio: 1.06; 95% CI: 0.74-1.54; P=0.745). CONCLUSIONS: Hydroxocobalamin administration was associated with reduced vasopressor requirement over 24 h, but not thereafter. Robust trials are needed to determine whether this relationship is causal, and whether a reduction in vasopressor use improves substantive clinical outcomes.
引用
- Zakaria L, Shah K, Yang D, et al. Hydroxocobalamin for vasoplegia in cardiac surgery: a retrospective cohort analysis. Br J Anaesth. 2025. PMID: 40634185. doi:10.1016/j.bja.2025.05.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。